84 results
Page 3 of 5
6-K
EX-99.1
msme16loo75b7k
27 Oct 21
InflaRx Announces Positive Data from Third Cohort of Phase IIa Open-Label Study with Vilobelimab in Pyoderma Gangraenosum
7:31am
6-K
EX-99.1
ngcu34w8vn um1bek
8 Sep 21
InflaRx to Proceed with Pivotal Development for Vilobelimab in Hidradenitis Suppurativa with New Primary Endpoint
7:30am
6-K
EX-99.1
jc27bmt
10 Aug 21
InflaRx Announces Positive Data from Second Interim Analysis
7:30am
6-K
EX-99.2
mjlzwi
5 Aug 21
Current report (foreign)
8:23am
6-K
EX-99.2
4kmkipi7mp0ybzlz83
12 May 21
Current report (foreign)
4:30pm
424B5
gmd33b908h59u
26 Feb 21
Prospectus supplement for primary offering
5:10pm
424B5
ensfd1 87l
24 Feb 21
Prospectus supplement for primary offering
5:16pm
6-K
rmbwrfmvv ycld
24 Feb 21
Current report (foreign)
4:16pm
6-K
EX-99.2
21z0sd3j0euehcee
11 Jan 21
InflaRx Provides Update on Vilobelimab (IFX-1) Development
7:30am
6-K
EX-99.2
jj1v95md
29 Oct 20
Current report (foreign)
7:05am
6-K
EX-99.1
de5ytxosoz
17 Sep 20
InflaRx Announces Leadership Team Additions with New CFO and Newly Created Position of Chief Strategy Officer
7:31am
6-K
EX-99.2
tipayiar
30 Jul 20
Current report (foreign)
7:36am
6-K
EX-99.3
cowj7f bvf2zka9en8
30 Jul 20
Current report (foreign)
7:36am
6-K
EX-99.1
z9578ebmb3mcqe 7z
21 Jul 20
InflaRx Announces Decision to Enter Phase III Development of IFX-1 in Severe COVID-19 Induced Pneumonia
7:35am
424B5
7482b003s5bpvubbxvcl
20 Jul 20
Prospectus supplement for primary offering
9:21am
F-3
gnjw9gvmwyj
8 Jul 20
Shelf registration (foreign)
12:00am
6-K
EX-99.1
gfd7nmqlt0 mpicy
17 Jun 20
InflaRx Reports Encouraging Topline Results from the Exploratory Phase II Part of the Adaptive Randomized Phase II/III Trial of IFX-1 in COVID-19
7:30am
6-K
EX-99.2
3kfw ptl4
21 May 20
Current report (foreign)
8:09am